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Abstract
Background Adverse events from Melody valve implanta-
tion may be catastrophic. To date a role for three dimen-
sional rotational angiography of the aortic root (3DRAA)
during Melody valve implantation has not been established.
Objectives To describe the role of 3DRAA in the assess-
ment of Melody valve candidacy and to demonstrate that it
may improve outcomes.
Methods All patients who underwent cardiac catheterisa-
tion for Melody valve implantation and 3DRAA between
August 2013 and February 2015 were reviewed.
Results 31 patients had 3DRAA with balloon sizing. Ten
were deemed not Melody candidates (5 coronary compres-
sion, 2 aortic root distortion with cusp flattening, 2 RVOT
was too large, and 1 had complex branch stenosis and
a short landing zone). Of the 21 patients who were Melody
candidates, 12 had conduits, 6 prosthetic valves and 3 na-
tive RVOTs. In patients with conduits, the technique of
stenting the conduit prior to dilation was used after mea-
suring the distance between the conduit and the coronary
arteries on 3DRAA. In the Melody patients, we had 100%
procedural success and no serious adverse events (coronary
compression, tears, stent fracture or endocarditis).
Conclusion As a tool for case selection, 3DRAA may facil-
itate higher procedural success and decreased risk of serious
adverse events. Furthermore, 3D rotational angiography al-
lows stenting of the conduit prior to dilation, which may
prevent tears and possibly endocarditis.
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Introduction
Since percutaneous pulmonary valve implantation was first
performed by Bonhoeffer in 2000 [1], its use has contin-
ued to expand. However, patients may be excluded because
of the risk of coronary artery compression. Conventional
two-dimensional angiography, including selective coronary
artery angiograms, may not definitively demonstrate coro-
nary artery compression during simultaneous right ventricu-
lar outflow tract (RVOT) balloon dilation because the lesion
is usually proximal and may be masked by the catheter in-
tubating the vessel [2–4]. Moreover, unsupported dilation
of stenotic and calcified conduits may result in ruptures or
tears requiring covered stents or urgent surgery [5]. The
use of three-dimensional rotational angiography (3DRA) in
the implantation of Melody valves has been primarily for
evaluation of the RVOT [6]. A role in imaging of the aortic
root including coronary arteries in this setting has not been
reported. The purpose of our study is to describe the use of
3DRA of the aortic root (3DRAA) and coronary arteries in
the assessment of Melody valve candidacy.
Methods
Sixty-nine patients have had percutaneous Melody valve
implantation at our institution since we started perform-
ing this procedure in October 2010 until February 2015
(68 in the pulmonary position and 1 in the tricuspid po-
sition). Since starting routine 3D rotational angiography
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Fig. 1 3D rotational angiography demonstrating calcium (green) surrounding the balloon (blue) in a patient with a single coronary artery. Note
the proximity of the calcium to the left anterior descending coronary in panel (a, b). Calcium surrounds the balloon in panel (c). Distance between
the balloon and the LAD is measured in panel (d)
in August 2013, 38 patients had a cardiac catheterisation
to assess for Melody valve candidacy. Of those 7 were
deemed not to be candidates for Melody valves on the
basis of a large RVOT prior to balloon sizing and thus
did not have a 3DRAA. Even though our focus is on the
31 who underwent 3DRAA, we include the 7 who did not
undergo 3DRAA for comparison of radiation dose using
the same catheterisation equipment (Table 1). All patients
had general anaesthesia and underwent an initial diagnostic
catheterisation including a pulmonary artery angiogram.
Technique of 3DRAA
If the RVOT was deemed adequate from the initial screening
pulmonary angiogram, 3DRAA was performed with simul-
taneous balloon sizing using a size 24 or 29 Amplatzer bal-
loon (AGA Medical Corp, Plymouth, MN, USA) or a low
pressure Max LD balloon (Cordis, Endovascular, Bridge-
water, NJ) in the RVOT over a Lunderquest (COOK Medi-
cal, Bloomington, IN, USA) or a Amplatz Super Stiff wire
(Boston Scientific, Marlborough, MA, USA). Right ventric-
ular pacing was performed at 180–200/min with breath hold
and an infusion rate of 16–18 cc/second for 6 s of a 60%
contrast to 40% saline concentration. We performed pacing
even though the cardiac output is stopped during balloon
inflation as we found it provides better balloon stability
and better filling of the coronary arteries. The images were
acquired with a C-arm mounted flat panel biplane angio-
graphic system (Toshiba America Medical Systems Inc.)
with non-gated, 190-degree rotational image acquisition.
Rendering and post-processing of the rotational images was
performed on a Vitrea Workstation (Toshiba America Med-
ical Systems Inc.). After post-processing, the image was
rotated until we found the view that showed the shortest
distance between the balloon and the coronary artery in
question. In some cases, we would start with the 3DRAA
with a sizing balloon; if the distance measured was small
or we were still concerned we would use the 3D image
to select the best angle to display the coronary/balloon re-
lationship, then insert a bigger balloon and do a selective
coronary angiogram. In most cases we would abort the
procedure based on the 3D rotation alone.
Technique of stenting the conduit prior to dilation
In patients with conduits, the technique of stenting the con-
duit prior to dilation was used. 3DRAA with a sizing bal-
loon was performed, after post-processing, the image was
rotated until we found the view that showed the shortest
distance between the balloon and the coronary artery in
question. The distance between the conduit and the coro-
nary artery in question was measured. Calcium between
the conduit and the coronary was assessed on the 3DRAA
images (Fig. 1 and 2). A safe distance was calculated based
on several factors. We assumed worst case scenario (that
the total expansion would occur in this area) and thus used
a balloon/stent size that would allow at least 4 mm clear-
ance from the coronary. The amount of calcium was also
taken into consideration. For example, if the narrowest area
of the conduit was 12 mm and the distance to the coronary
in question was 8 mm with no or little calcium, we stented
the conduit with a 16 mm stent and if the distance was
6 mm or it was 8 mm with heavy calcium we used a 14 mm
stent (Fig. 1 and 2; Table 3). We subsequently re-evalu-
ated the coronary in question and if a distance of more than
4 mm was still present we further serially dilated the stent
to achieve the safest maximum diameter for the Melody
valve, rather than a predetermined diameter. In some cases,
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Fig. 2 3D rotational angiogra-
phy (blue: balloon in the right
ventricular outflow tract, yellow:
aortic root and coronary arteries,
green: conduit calcification),
demonstrating the distance be-
tween the calcium surrounding
the balloon and the LMCA in
two angled views showing the
same measurement of 5.8 mm
we chose to only implant an 18 mm Melody valve instead
of a 20 or 22 if the coronary artery was too close. Palmaz
stents (Cordis, Endovascular, Bridgewater, NJ, USA) were
used in this group because of their higher radial strength.
Several stents are placed in the landing zone until no recoil
was observed on fluoroscopy. As adding stents increases the
outer diameter, which will get even bigger after implanta-
tion of the valve, if there was concern about the distance
between the coronary and the balloon, the first stent was
placed at a diameter smaller than the desired final diameter
and a selective angiogram of the coronary in question was
done before enlarging it further. This was done on a case by
case basis and depended on how close the coronary artery
was.
Technique for melody valve implant in bio-prosthetic
valves
3DRAA and coronary distance were assessed and the usual
precautions were taken. Pre-stenting with Palmaz stents
was performed; usually only one stent was needed because
there is support from the valve stent and fracture is unlikely.
Technique for melody valve implant in native RVOT
3DRAA and coronary distance was assessed. Pre-stenting
with EV3 stents (Covidien/Metronic, Minneapolis, MN)
was performed. These stents were selected because their
open cell design allows them to conform better to the
anatomy than Palmaz stents. Furthermore, these patients
generally did not have stenosis, so less support was needed.
Data collection
Pre-procedure data included age, weight at implant, origi-
nal diagnosis, past operations, type/size of last conduit or
valve placed, degree of conduit stenosis and/or regurgita-
tion by echo and MRI if available. Data collected from the
3DRAA included coronary artery pattern, proximity of the
coronaries to the sizing balloon, distance from the inflated
balloon to the closest coronary artery, aortic cusp com-
pression, as well as radiation dose for 3DRAA. The study
was conducted with approval by the University of Califor-
nia San Diego Institutional Review Board, and patient data
collection and storage complied with the Health Insurance
Portability and Accountability Act of 1996.
Comparing radiation dose for 3DRAA with 2D
angiography
The radiation exposure during the entire procedure of the 31
patients who underwent 3DRAA was compared with that
of the 7 patients who were not deemed to be Melody can-
didates and only underwent 2D conventional angiograms.
Statistics
Statistical analysis includes rates of incidence as a propor-
tion. Statistical significance was assessed by Fisher’s exact
test and Student’s t-test for categorical and continuous vari-
ables respectively. All tests were two-sided and a p-value
of less than 0.05 considered significant.
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Fig. 3 a 3D rotational angiogram demonstrating the close relationship of the sizing balloon and the left main coronary artery in a patient with
Ross and a dilated aortic root. This was used to determine the best angle to perform the selective coronary angiogram. A selective left coronary
angiogram in the angle determined by the 3D rotation with a high pressure balloon 2 mm larger than the waist on the sizing balloon. Note coronary
compression with balloon inflated (c) compared with with the balloon deflated (b)
Fig. 4 a 3D rotational angiogram demonstrating aortic root distortion and coronary cusp flattening, this was used to determine the angle that
best showed the cusp compression. An aortogram of the same patient in the angle determined by the 3D rotation demonstrating cusp distortion/
compression with the balloon inflated (b) and no cusp compression with the balloon deflated (c). The right coronary artery appears to be slightly
distorted but not significantly compressed with balloon inflated. Patient was turned down for Melody implantation based on cusp compression/
distortion
Results
Of the 31 patients who had 3DRAA, 10 were deemed not
to be candidates for a Melody valve: 5 because of coro-
nary compression (Fig. 3), 2 because of aortic root distor-
tion with cusp flattening (without coronary compression)
(Fig. 4), 2 because the RVOT was too large, and 1 had
complex pulmonary artery branch stenosis and a very short
landing zone (Table 2). Of the 21 who were deemed candi-
dates for Melody valve implantation, 12 had conduits (Ho-
mograft 9, Contegra 3), 6 had bio-prosthetic valves and
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Table 1 Patient demographics for patients who underwent 3DRA divided in to Melody eligible and ineligible groups
Ineligible group n = 10 Melody group n = 21 P-value
Sex 0.86
Male 7 14 –
Female 3 7 –
Age (years) 1
Average 15.9 16.6 –
Median 10 14 –
Range (min–max) (3–58) (5–39) –
Weight 0.06
Average 38.5 56 –
Median 30 50 –
Range (min–max) (12.5–86) (19–125.3) –
Diagnosis 0.58
TOF (or Variant) 5 12 –
Truncus Arteriosus 1 3 –
Othera 4 5 –
Arch side 0.003
Left 10 12 –
Right 1 9 –
Type of RVOT 0.0038
Native 5 3 –
Contegra 3 3 –
Homograft 2 9 –
Bioprostheticb 0 6 –
Indication for PVR 0.269
Stenosis 3 6 –
Regurgitation 6 6 –
Both 1 9 –
NS not significant where p = <0.05
aOther includes: bicuspid aortic valve s/p Ross procedure, severe pulmonary stenosis, pulmonary atresia with intact ventricular septum, atrioven-
tricular canal with pulmonary stenosis, Heterotaxy syndrome with double outlet right ventricle and pulmonary atresia
bBioprosthetic valves include: the Mitroflow Valve, Edwards Perimount Valve, Mosaic Valve, PVR pulmonary valve replacement
3 had a native RVOT with a transannular patch (Table 1
and 3).
Of the 21 patients deemed to be eligible for a Melody
valve, all underwent successful Melody valve implantation
(100% procedural success). There were also no serious ad-
verse events: i. e. no patients had coronary artery compres-
sion, conduit tears or conduit ruptures. In selected patients
in which the distance to the coronary artery was in ques-
tion, we elected to use an 18 mm valve instead of a 20 or
22 mm. Despite this conservative approach, the 3 patients
who received an 18 mm valve had no significant residual
gradients (13,15 & 16 mm Hg).
At follow-up, all of the implanted Melody valves remain
in situ with no patients to date requiring explant or re-
intervention on their valve. There have been no cases of
infectious endocarditis, no cases of stent fracture in this
cohort, and no significant re-stenosis or regurgitation after
an average of 1.2 years follow-up (range 0.9 to 1.8 years).
When comparing the group that received 3DRAA (n =
31) and the one who only received 2D conventional angiog-
raphy (n = 7), we observed that the relationships of radia-
tion exposures between the two imaging modalities differed
based on patient weight. Sub-analysis taking patient weight
into account showed that for patients weighing less than
50 kg, the radiation exposure for 3D rotational angiography
(expressed in dose area product cmGy*m2) was higher than
that for the 2D angiography (p = 0.00782). Conversely,
for patients heavier than 50 kg, there was a higher radia-
tion dose area product during 2D conventional angiograms
compared with 3D rotational angiograms (p = 0.03821).
Discussion
In this report, procedure success was 100% among patients
selected for Melody valve implant using 3DRAA. Further-
more, in these patients, there were no serious adverse events
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Diagnosis Procedure #Surg Conduit type Size DysfX Reason not im-
planted
1 15 38 TOF/PA Unifoc/Repair 2 Contegra 18 S RVOT too large
2 13 31 TA/IAA Repair/conduit
X2
2 Homograft 15 R RCA compression
3 58 76 Bicuspid
aortic
valve
s/p Ross 1 Homografta Unknown S LMCA compression
4 8 24.8 d-TGA,
VSD
s/p Rastelli 1 Contegra 14 R Conal branch com-
pression
5 9 52 TOF s/p repair- no
TAP
3 Contegra 22 S Technical challenge
with branch PAs
(short MPA)





0 Native NA R RVOT too large
7 5 15.7 TOF, PA s/p TAP 2 Transannular
patch
NA R RCA compression
8 32 86 TOF s/p TAP 2 Transannular
patch
NA R Right coronary cusp
flattening and distor-
tion of RCA







NA R RCA compression








NA S&R Right coronary cusp
flattening and distor-
tion of RCA
aPresumed homograft; ASD atrial septal defect, BT Blalock Taussig shunt, CS coronary sinus, DysfX conduit dysfunction, IAA interrupted aortic
arch, L left, LMCA left main coronary artery, LPA left pulmonary artery, LSVC left superior vena cava, MPA main pulmonary artery, NA not
applicable, PA pulmonary atresia, PAs pulmonary arteries, PV pulmonary valve, R regurgitation, RCA right coronary artery, RVOT right ventricular
outflow tract, S stenosis, s/p status post, TA transannular, TAP transannular patch, TGA transposition of great arteries, TOF tetralogy of Fallot,
VSD ventricular septal defect
during the procedures or in the short to medium term fol-
low-up. Although our case series is small, we believe that
the methodology described in our report provides a more
rigorous selection process and allows procedures to be per-
formed more safely than do the conventional methods. [3,
13].
Our candidate selection rate for Melody valve implanta-
tion was 73%, which is somewhat lower than in previous
reports (83%) [2]. We believe that the lower selection rate
was the result of several factors: first, we evaluated a wider
range of patients than those specified in the US Food and
Drug Administration (FDA) labelling. Second, we relied
on 3DRAA for the assessment of potential coronary com-
pression rather than on conventional angiography. Third, in
addition to the typical eligibility criteria, related to vessel
size and coronary artery compression, we also eliminated
patients because of likely significant aortic root or cusp
distortion.
Our early patients met the selection criteria defined by
the device’s FDA cleared labelling. These patients had
failed or failing right ventricle to pulmonary artery con-
duits and were generally nearly adult sized. However, as
our experience grew the range of patients we considered
expanded. We evaluated and are reporting here patients
with a native RVOT (n = 12), only three of which had an
RVOT that was suitable for Melody valve implant. In ad-
dition, we evaluated very small patients for Melody valve
implantation, our smallest patient weighing only 12.5 kg.
The rate of disqualification for Melody valve implanta-
tion because of coronary artery compression in our series
since we began relying on 3DRAA assessment of coronary
arteries was 13% (5/38). This is higher than the previously
reported rates of 1 to 6%. [2, 3, 7–9]. Abnormal coro-
nary artery patterns present higher risks for coronary artery
compression [10]. However, none of our disqualified pa-
tients had such coronary artery patterns. We believe that our
method of assessing the risk of coronary artery compression
by 3DRAA is more conservative and may provide a greater
safety margin than the conventional methods. Our belief is
supported by recent studies in patients with coronary artery
disease which suggest that the use of 3DRAA may provide
assessment of coronary artery lesions, which is superior to
assessment by conventional coronary angiography [11–15].
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36 PS 21,S 17 LM 8.6 PZ/2 22 22 Atlas 22 N 35 12





14 LM 13.8 PZ/3 20 22 Atlas 22 None 32 17
8 TOF
18,SR
14 LAD 10.6 PZ/3 18 18 Atlas 18 None 23 13
13 TOF 21,R 17 RCA 12 PZ/2 22 None 22 None 7 11
13 TOF
UK,SR
12 RCA 9.5 PZ/2 16 16,18
Atlas
18 None 15 15
15 TA 20,R 15 RCA 7.4 PZ/2 20 20 Atlas 20 None 17 15
24 TOF 26,R 20 RCA 9 PZ/2 22 None 22 None 7 0
13 TOF 16a,S 12 NA CR PZ/2 20 20 Atlas 20 None 36 14
23 TOF
22a,SR





8 PZ/3 16 None 18 Y-18
Atlas
29 16
aContegra, all others were homografts; Ball post st balloon used post stent placement, BIB balloon in balloon, BPM balloon post Melody im-
plantation, C conduit size, DF conduit dysfunction, Dist from CA distance from coronary artery, DORV double outlet right ventricle, Dx diag-
nosis, Gr gradient, LAD left anterior descending, LM left main, MSz Melody size, NA not applicable, NBD narrowest balloon diameter, Prox to
CA proximal to coronary artery, PS pulmonary stenosis, PZ Palmaz stent, R regurgitation, RCA right coronary artery, S stenosis, SR stenosis and
regurgitation, St stent, TA truncus arteriosus, TOF teratology of Fallot, UK unknown
As more sophisticated coronary artery imaging tech-
niques emerge, there may be risk that patients will be dis-
qualified for Melody valve implantation based on anatomic
findings of questionable clinical significance. We believe
that the existing reports demonstrate the need for improved
coronary assessment. Several series, including the sen-
tinel US FDA clinical trial [17], contain anecdotal patients
which demonstrate clinical coronary artery compression af-
ter valve implant. There are also notable cases of patients
whose coronary arteries were evaluated using conventional
methods, who presented with clinically significant coro-
nary artery compression up to one-year post implantation
[10]. Furthermore, implant procedures are performed in
the artificial state of general anaesthesia with controlled
heart rates and low cardiac outputs. Certainly in patients
who are awake and exercising the aorta and the pulmonary
artery increase in size and coronary circulation may undergo
compromise not experienced under anaesthesia. For these
reasons, we believe that the more conservative and exact-
ing standard offered by use of 3DRAA provides a safer and
a more appropriate assessment of susceptibility to coronary
compromise than does conventional coronary angiography.
Clearly, even using 3DRAA, there are borderline cases.
In such cases, we have usually elected to implant the valve
at the smallest nominal diameter (18 mm) and have avoided
upsizing to 20 or 22 mm in spite of small residual post-im-
plant gradients (13–16 mm Hg). We believe that this prac-
tice may provide an additional margin of safety, and in such
patients, mild residual stenosis is well tolerated and allows
for clinical improvement over pre-implant clinical status.
A further criterion we have used to assess eligibility for
Melody valve implantation is aortic root and cusp flattening
or distortion. This is well assessed by 3DRAA, and not as-
sessed by conventional coronary or aortic angiography. We
disqualified two patients because we were concerned that
distortion or cusp flattening might cause long-term sub-crit-
ical coronary insufficiency and lead to ventricular dysfunc-
tion. We believe that patients reported with dynamic coro-
nary artery compression during exercise following Melody
valve implantation support this concern [10]. In addition,
subtle distortion of the aortic root may also lead to aortic
valve insufficiency and dysfunction [16]. For these reasons,
our current practice is to disqualify patients with significant
aortic root compression for Melody valve implantation.
Turning to technical aspects of Melody valve implanta-
tion, in our experience, standard use of 3DRAA exposes
patients to similar doses of angiographic contrast and radi-
ation as do standard aortic and coronary angiography. For
3DRAA, we use a ratio of 60% angiographic contrast to
40% saline. This allows higher volume injections with less
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contrast. We have found the images are clearer and easier to
clean up when using this formula. Also, only one 3D image
is required, as opposed to the multiple images which may
be needed in standard angiography. Finally, we have found
that pacing induced hypotension, as well as balloon RVOT
occlusion combine to provide much cleaner images of the
aortic root and coronary arteries. One additional factor here
is the very large aortic roots characteristic of tetralogy of
Fallot and truncus arteriosus, which must be defined by the
3DRAA.
In our series, the total radiation dose was not different
between the cases using 3DRAA and the conventional 2D
imaging approaches. Other studies also confirm that use
of 3DRAA does not increase overall radiation exposure to
patients over use of conventional angiography [11–15]. In-
terestingly our experience suggests that in patients weighing
more than 50 kg, there is actually less radiation exposure
used to acquire the 3D rotational angiograms as compared
with conventional angiography.
Since 2013, 3D rotational angiography provided the prin-
ciple tool in assessment of Melody valve candidacy in our
institution. This imaging modality offers detailed coronary
artery assessment in all planes. Once the rotational image
is acquired it can also be employed to determine the best
working angle for evaluation of the coronary artery in ques-
tion during balloon dilation or stent implantation. Addition-
ally, more precise assessment of the coronary artery course
and distance to the RVOT/conduit allows for safer Melody
valve implantation. 3D rotational angiography also pro-
vides a 3D assessment of the calcification patterns through-
out the RVOT, which we also factor into our assessment of
areas at risk for tears or ruptures.
An additional benefit of routine use of 3DRAA is that
it allows us to stent the conduits early in the valve implant
procedure at a small diameter, prior to serial high-pres-
sure balloon dilation in preparation for valve implantation.
This can only be done after accurate 3D understanding of
the coronary artery anatomy and precise measurement of
the distance from the area of narrowing and the coronary
artery in close proximity is performed. This approach of
early stenting of the conduit is inverted from the more stan-
dard approach of initial high-pressure balloon dilation of the
conduit until the desired Melody implant size is achieved
and the stent landing zone is laid down [8, 17–19]. The
advantage offered by our technique is that conduit walls
are stabilised by the stent, tears or disruptions are likely to
be more limited, and placement of covered stents to abort
a crisis is less complex. We believe that our approach max-
imises the structural integrity of the conduit and minimises
the risk of major conduit tears and ruptures from initial bal-
loon dilation. In our limited experience, we have not had
a major or catastrophic conduit disruption to date, whereas
this complication has been reported in 1.4–2.7% of patients
in other case series [19–21]. Certainly, the absence of this
relatively rare complication may be because of our rela-
tively small patient cohort. However, we advocate this
method from first principles and urge others to consider
adopting it.
Conclusion
Three dimensional rotational angiography appears to be
a valuable tool for case selection among Melody valve can-
didates. It may facilitate higher procedural success and
reduce the risk of serious adverse events. Furthermore,
3D rotational angiography allows stenting of the conduit
prior to dilation, which may prevent tears and possibly en-
docarditis. Additional studies are needed to confirm our
findings.
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